Drug Type Synthetic peptide |
Synonyms NS 300, NS300 |
Target |
Action modulators |
Mechanism TAFA5 modulators(TAFA chemokine like family member 5 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Autistic Disorder | Preclinical | South Korea | - | |
| Epilepsy | Preclinical | South Korea | - | |
| Neuralgia | Preclinical | South Korea | - | |
| Schizophrenia | Preclinical | South Korea | - | |
| Sensation Disorders | Discovery | United States | 01 Jan 2025 |






